People search 'CagriSema reconstitution' for a reason that the search results rarely address honestly: cagrilintide and semaglutide are both sold as lyophilized research-grade powders by gray-market vendors, and some vendors go further, selling single vials marketed as 'CagriSema' blends of the two. The searcher wants a number — how much bacteriostatic water, how many units on the syringe. Here is the load-bearing fact that almost every ranking page omits: CagriSema is a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg that is still investigational. Its New Drug Application has been under FDA review since December 18, 2025. No approved product exists, so no approved labeling exists, so no official reconstitution specification can exist. Anything that presents one is describing a home preparation, not CagriSema.
What can be stated honestly is three things, and they are what this guide delivers. First, the status context: what CagriSema is, what the REDEFINE program showed, and why a decision is anticipated by late 2026 — PeptaHub maintains a dedicated tracker for that. Second, the arithmetic that governs any reconstituted vial of either component compound separately — concentration math, insulin-syringe unit conversions, and worked examples at vial sizes actually sold in the research-grade market, built on the same foundation as our general guide to reconstituting peptides. Third, what changes if a fixed-dose commercial product is approved: the entire calculation disappears, because the product would arrive as a pre-filled pen, not a vial.
The math sections use the doses studied in the REDEFINE trials (2.4 mg of each component) purely as arithmetic illustrations — the only grounded reference numbers that exist — not as recommendations. This guide is educational only. It provides no dosing, no protocol, no sourcing guidance, and nothing in it should be read as encouragement to use any investigational or research-grade substance.
Side-by-side comparison
| Compare | Reconstitution ratio | Per 1 unit (0.01 mL) | Per 10-unit mark (0.1 mL) |
|---|---|---|---|
| 5 mg vial + 2 mL BAC water (2.5 mg/mL) | 2,500 mcg/mL; 25 mcg per unit | 250 mcg | A 2.4 mg amount = 2,400 mcg = 96 units (0.96 mL) |
| 5 mg vial + 1 mL BAC water (5 mg/mL) | 5,000 mcg/mL; 50 mcg per unit | 500 mcg | A 2.4 mg amount = 48 units (0.48 mL) |
| 2 mg vial + 2 mL BAC water (1 mg/mL) | 1,000 mcg/mL; 10 mcg per unit | 100 mcg | A 2.4 mg amount = 240 units — exceeds a 1 mL syringe and the vial's total content |
| 2 mg vial + 1 mL BAC water (2 mg/mL) | 2,000 mcg/mL; 20 mcg per unit | 200 mcg | A 2.4 mg amount = 120 units — exceeds a 1 mL syringe and the vial's total content |
| Pre-mixed compounded semaglutide, 2 mg/mL | 2,000 mcg/mL; 20 mcg per unit — no reconstitution needed | 200 mcg | A 0.25 mg amount = 12.5 units (matches the worked example in our reconstitution guide) |
Syringe-unit conversions for common reconstitution ratios, on a U-100 insulin syringe (100 units = 1 mL; each unit = 0.01 mL, each 10-unit mark = 0.1 mL). Illustration: at 2.5 mg/mL, the 2.4 mg per-component amount studied in REDEFINE corresponds to 0.96 mL — 96 units, nearly a full 1 mL syringe.
What CagriSema is — a co-formulated product, not a mixing recipe
CagriSema is Novo Nordisk's once-weekly subcutaneous combination of cagrilintide 2.4 mg — a long-acting amylin analog — and semaglutide 2.4 mg, a GLP-1 receptor agonist already marketed for weight management as Wegovy. The two components act on different satiety systems, which is the entire rationale for combining them. In the REDEFINE-1 phase 3 trial (3,417 adults with overweight or obesity; results announced December 2024 and published in the New England Journal of Medicine in 2025), the combination produced a 22.7% mean weight reduction at 68 weeks versus 2.3% on placebo under the trial product estimand (20.4% versus 3.0% regardless of adherence), outperforming arms that received cagrilintide 2.4 mg alone or semaglutide 2.4 mg alone. The trial is registered as NCT06065540.
The critical word for this guide's question is 'fixed-dose combination.' In the trials, CagriSema was administered as a single co-formulated injection manufactured under Good Manufacturing Practice — one pharmaceutical product containing both molecules at a fixed 1:1 ratio, supplied in clinical-trial packaging. It was not two vials mixed at a pharmacy bench, and it was not a user-reconstituted powder. That distinction is not cosmetic: co-formulation determines whether both peptides remain stable together in solution, at what ratio, and for how long — properties that are established by the manufacturer's analytical work and locked into the approved product, not improvised afterward.
As of this guide's October 2026 publication, CagriSema is investigational. The NDA filed December 18, 2025 for weight management remains under FDA review; Novo Nordisk's February 23, 2026 SEC filing says a decision is 'anticipated by late 2026,' and no PDUFA goal date has been made public. PeptaHub's CagriSema FDA approval tracker maintains the full dated record, and our CagriSema vs tirzepatide and CagriSema vs semaglutide comparison pages carry the head-to-head data.
Why no official reconstitution spec exists — and cannot yet
A reconstitution specification is not a standalone fact; it is a component of an approved product's labeling. It specifies the diluent, the volume, the resulting concentration, the handling window, and the storage conditions — and every one of those statements carries the weight of FDA review of stability, sterility, and compatibility data for that exact presentation. That is why your Wegovy or Ozempic pen arrives with instructions and your compounded semaglutide vial arrives with a labeled concentration: an approved or pharmacy-prepared product comes with the specification attached.
CagriSema has no approved presentation, so it has no specification of any kind. There is no FDA-reviewed diluent, no official bacteriostatic water volume, no validated concentration, no beyond-use dating. The only CagriSema that has ever existed outside Novo Nordisk's clinical-trial supply chain is whatever someone assembles from separately purchased research chemicals — which brings the discussion to the honest core of this topic: 'CagriSema reconstitution' as an activity exists only in the research-grade gray market, and nothing performed there re-creates the trial product.
The commercial trajectory points the opposite direction from vials and mixing. Approved semaglutide products ship as pre-filled, single-dose pens that require no reconstitution at all, and compounded semaglutide is typically supplied already in solution at a labeled concentration such as 2 mg/mL. Novo Nordisk's launch picture for CagriSema, as tracked since the filing, is likewise a pen-device format. If the FDA approves the NDA, the product that reaches pharmacies will eliminate the reconstitution question entirely: a fixed dose in a fixed device, with the label doing the arithmetic. The math below matters precisely because it describes the interim period — an investigational combination whose components circulate as unregulated powders — not the end state.
The dilution math, part one: research-grade cagrilintide
Cagrilintide is sold by research-chemical vendors as a lyophilized powder, most commonly in 5 mg vials. Whatever one thinks of that market, the arithmetic that governs such a vial is standard and worth stating precisely. It is the same math laid out in our guide to reconstituting peptides: concentration equals total peptide divided by added solvent, and on a U-100 insulin syringe, 100 units equals 1 mL, so each unit is 0.01 mL.
Worked example, using the vial size the market actually sells: a 5 mg vial (5,000 mcg) reconstituted with 2 mL (200 units) of bacteriostatic water yields 5,000 / 2 = 2,500 mcg/mL, or 2.5 mg/mL. Per syringe unit, that is 2,500 x 0.01 = 25 mcg per unit; per 0.1 mL tick (10 units), 250 mcg. The general formula for any target mass: units to draw = (desired mcg / total mcg in vial) x units of water added — and note the property that trips people up: the water volume changes the concentration, never the total amount of peptide in the vial. Adding 4 mL instead of 2 mL does not create more cagrilintide; it halves the concentration to 1.25 mg/mL and doubles every volume you would draw.
To show how the trial figures translate through this arithmetic — as a calculation exercise, not a protocol: the 2.4 mg cagrilintide dose used in REDEFINE corresponds, at the 2.5 mg/mL concentration above, to 2,400 / 25 = 96 units, or 0.96 mL — nearly the entire capacity of a 1 mL insulin syringe in a single draw. That single result explains more about the product's design than any vendor page does: fixed-dose pens exist so that this calculation is never performed by the person holding the injector. For checking any ratio against your own vial, PeptaHub's dosing calculator and cagrilintide dose page do the arithmetic automatically.
The dilution math, part two: research-grade semaglutide
Semaglutide research-grade powder is commonly sold in 2 mg vials, which changes the arithmetic meaningfully. Reconstitute a 2 mg vial (2,000 mcg) with 2 mL of bacteriostatic water and the concentration is 2,000 / 2 = 1,000 mcg/mL, or 1 mg/mL — 10 mcg per unit, 100 mcg per 0.1 mL tick. Run the same trial-figure illustration through it: a 2.4 mg amount at 1 mg/mL is 2,400 / 1,000 = 2.4 mL, or 240 units. That exceeds a 1 mL (100-unit) insulin syringe more than twofold — and, more fundamentally, it exceeds the vial: a 2 mg vial contains 2 mg, full stop. No dilution scheme extracts 2.4 mg from it.
This is the practical lesson of the math, and it applies to any peptide vial: run the concentration arithmetic against the mass you intend to work with before choosing a vial size or a water volume, because mismatches reveal themselves as un-drawable volumes mid-preparation. Our reconstitution guide's worked examples walk the same logic for BPC-157 and ipamorelin, and the identical formula governs here.
One more piece of context keeps the semaglutide side honest: unlike cagrilintide, this component already exists as an approved, labeled pharmaceutical. Semaglutide 2.4 mg once weekly is Wegovy's chronic weight-management dose, and pharmacy-compounded semaglutide is typically supplied pre-mixed at a stated concentration — commonly 2 mg/mL — rather than as powder, in which case no reconstitution happens at all and the math reduces to reading a label. On a 2 mg/mL solution, 20 mcg per unit means a 0.25 mg amount corresponds to 12.5 units — precisely the worked example in our general reconstitution guide. The existence of an approved pathway for one component while the combination remains investigational is exactly the asymmetry that makes 'CagriSema reconstitution' such a loaded search: half of the combo has a regulated route, and the combo itself has none.
Mixing cagrilintide and semaglutide in one vial: what is and is not known
A meaningful share of this query family is not 'how do I dilute each vial' but 'how do I combine them' — cagrilintide plus semaglutide mixing. The honest answer has two parts, and both are statements about evidence, not instructions in either direction.
First: no published compatibility or stability data exists for mixing separately purchased cagrilintide and semaglutide powders into one solution. Whether two peptides remain chemically intact when co-dissolved, at what ratio, over what storage window, is an analytical question that manufacturers answer with validated stability testing. For a user-assembled combination, no such testing has ever been published. This is why our general reconstitution guide's rule is that combining peptides in one syringe or vial is not recommended without established compatibility data for the specific pair — and cagrilintide plus semaglutide has none outside Novo Nordisk's proprietary work on the co-formulated product.
Second: the co-formulated product is not 'the two powders mixed.' CagriSema's clinical material is a single GMP-manufactured presentation with both molecules at a fixed 1:1 ratio (2.4 mg / 2.4 mg) and a stability profile its manufacturer validated and regulators reviewed. Gray-market vials marketed as 'CagriSema blends' — some vendors list them as 5 mg of each peptide in one lyophilized cake — carry no public data on whether the blend survives reconstitution intact, whether the ratio matches anything studied, or whether the vial was filled under any sterility standard at all. A claim that a home mixture or a vendor blend is 'equivalent to CagriSema' is not a conservative simplification; it is an unevidenced equivalence claim about two different physical products. The REDEFINE results attach to the co-formulated presentation, and to nothing else.
Stated plainly: this guide neither tells you to mix nor promises you shouldn't — it records that the information needed to do either responsibly does not exist in public. When the only defensible answer to 'is this safe?' is 'no one has measured it,' that is itself the answer a searcher needs before touching two vials.
Storage and handling: the same rules as any reconstituted peptide
Nothing about CagriSema's investigational status changes the physics of a reconstituted vial, so the handling rules are the standard ones from our reconstitution guide, restated here because searchers arriving from a CagriSema page often skip the general guide.
Bacteriostatic water — sterile water with 0.9% benzyl alcohol — is the only appropriate solvent for a multi-use vial; the preservative is what extends the usable window to roughly 28-30 days under refrigeration, and plain sterile water forfeits that protection entirely. Reconstituted vials are refrigerated at 2-8 degrees Celsius, never frozen (ice crystals shear peptide structure, and freeze-thaw cycles compound the damage), and never shaken — dissolve by letting water run down the vial wall and waiting, rolling gently only if needed. Because both components here are large peptides that degrade with heat, light, and time, vials should be dated at reconstitution, protected from prolonged light exposure, and treated as expired after the 28-day window regardless of remaining volume. A vial of an investigational drug candidate that has been stored outside these conditions has no salvage story: there is no reference standard to test it against, and no one to ask.
Two handling points deserve extra weight in this specific context. The sterility chain is only as good as its weakest vendor: research-grade cagrilintide and semaglutide vials are filled outside any pharmaceutical oversight, so the contamination risk starts before reconstitution does. And the absence of any label means there is no beyond-use date, no concentration printout, no lot recall — the notebook discipline (date, water volume, computed concentration) that is merely good practice for compounded products becomes the only record that exists for a gray-market vial.
What changes if the FDA approves CagriSema
Somewhere in late 2026 — the only on-record timing language is Novo Nordisk's 'anticipated by late 2026' from its February 23, 2026 SEC filing; no PDUFA date has been published — the FDA will act on the CagriSema NDA. If the action is an approval, every question on this page collapses into a label.
An approved CagriSema would arrive as a pre-filled pen at fixed doses, the format the entire class already uses and the one Novo Nordisk has trailblazed across Ozempic, Wegovy, and Saxenda. Reconstitution as a user task disappears; the concentration math disappears; the mixing question disappears — replaced by a label that states dose, storage, and handling because regulators reviewed the data behind each statement. The gray-market vials would not disappear, but they would lose their last framing excuse: the argument 'people need to mix their own because no product exists' expires on approval day, and what remains selling powder after that is simply competing with a regulated medicine.
If the action is a complete response letter or a delay, the interim state this guide describes extends — and the math sections above remain the only honest content available: arithmetic for two separate compounds, an unmeasured mixing question, and no official specification. Either way, PeptaHub's CagriSema FDA approval tracker will record the decision and what it changes, and the head-to-head pages — CagriSema vs tirzepatide and CagriSema vs semaglutide — carry the comparative numbers. The reconstitution question, unlike the approval question, has no decision date: it resolves instantly the day a pen ships, or not at all.
Frequently asked questions
No, and there cannot be one yet. CagriSema — cagrilintide 2.4 mg plus semaglutide 2.4 mg, once weekly — is investigational: its NDA (filed December 18, 2025) is still under FDA review, with a decision anticipated by late 2026 and no PDUFA date published. A reconstitution specification is part of an approved product's labeling, so no official diluent, volume, or concentration exists. Any page presenting an 'official' CagriSema reconstitution spec is describing a home preparation of research chemicals, not the trial product.
As pure arithmetic: 5 mg in 2 mL gives 2.5 mg/mL (25 mcg per unit on a U-100 syringe), so a 2.4 mg amount is 2,400 / 25 = 96 units — 0.96 mL, nearly a full 1 mL insulin syringe. This is a calculation illustration using the per-component dose from the REDEFINE trials, not a dosing recommendation. The same arithmetic also shows why the commercial product is a fixed-dose pen: volumes near a full syringe are exactly what pens exist to eliminate.
No published compatibility or stability data supports it. The clinical-trial product is a single co-formulated injection manufactured under GMP at a fixed 1:1 ratio — not two powders combined after the fact — and its stability was established by the manufacturer's validated testing. For user-mixed cagrilintide plus semaglutide, no such testing has ever been published, and vendor-sold 'CagriSema blend' vials provide no public data on ratio, stability, or sterility. The REDEFINE results attach to the co-formulated product only; a home mixture or gray-market blend is not an evidenced equivalent.
It depends entirely on how much bacteriostatic water you add — the water sets the concentration, never the peptide content. 5 mg (5,000 mcg) plus 2 mL yields 2.5 mg/mL (25 mcg per unit; 250 mcg per 0.1 mL); plus 1 mL yields 5 mg/mL (50 mcg per unit). Choose the volume so the amounts you work with fall on easy-to-read syringe markings: large weekly-mass doses favor more dilute solutions, because concentrated ones can exceed the 1 mL (100-unit) syringe. PeptaHub's dosing calculator converts any ratio instantly.
About 28-30 days at 2-8 degrees Celsius when bacteriostatic water (0.9% benzyl alcohol preservative) is used — the preservative sets that window, which is why plain sterile water is unsuitable for multi-use vials. Never freeze a reconstituted solution, never shake it to dissolve, and label every vial with its reconstitution date so the clock is visible. After the window, discard regardless of remaining volume.
No. As of this guide's October 2026 publication, CagriSema remains investigational in the United States. The weight-management NDA filed December 18, 2025 is under review, Novo Nordisk's SEC filing language ('anticipated by late 2026') is the only on-record timing signal, and no PDUFA goal date has been announced. PeptaHub's CagriSema FDA approval tracker maintains the dated record and updates when the decision lands.